開拓藥業(09939.HK):業務一切正常 第四季完成普克魯胺中期分析
開拓藥業(09939.HK)上週五股價急挫,董事長兼行政總裁童友之在投資者溝通會上表示,留意到股價波動,但強調業務一切正常進行。
他表示,得悉市場上有出現關於旗下產品普克魯胺三期臨牀結果的消息,指出疫情下市場於有效治療新冠的口服藥物十分關心,目前正全力推進多項註冊性臨牀試驗,希望讓藥物能夠儘快取得緊急使用授權(EUA)。
童友之透露,普克魯胺正進行三個三期全球多中心臨牀試驗,兩個針對輕中症,一個針對重症,進展最快的是在美國等8個國家開展的輕中症臨牀試驗;其中輕中症MRCT計劃的樣本量達660多人,目前已入組超過300人,預期今年第四季完成中期分析及整個臨牀試驗受試者入組,以獲得陽性結果,之後可在多個國家能夠獲批EUA及上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.